Boston Scientific slides after quarterly sales of key products disappoint

Shares of medical device maker Boston Scientific BSX.N tumble 14% to $78.72

Stock set for its biggest pct fall in over 5 years, if losses hold

BSX expects 2026 adjusted EPS of $3.43 to $3.49, the midpoint of which is below analysts' average estimate of $3.47 - LSEG-compiled data

Sees net sales growth between 10.5% and 11.5% for 2026, slower than its 19.9% growth in 2025

Electrophysiology franchise (EP) sales of $890 million below Street estimates of $933 million, according to RBC analysts

Sales of Watchman, co's stroke prevention device, came in 1% below consensus with U.S. market entirely responsible for the miss, at least three analysts said

"Investors now have reason to question the trajectory of these two key growth drivers moving forward" - brokerage J.P. Morgan, referring to EP and Watchman businesses

Stock recently traded at 26.1 times expected earnings, vs its five-year avg forward PE of 26.9, suggesting it may be close to fairly valued, per LSEG data

BSX reports Q4 EPS of 80 cents vs. average estimate of 78 cents

Shares fell ~7% in 2025